Publications
Detailed Information
A combination treatment with SAHA and ad-p63/p73 shows an enhanced anticancer effect in HNSCC
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shim, Seon-Hui | - |
dc.contributor.author | Lee, Choon-Taek | - |
dc.contributor.author | Lee, Jae-Jung | - |
dc.contributor.author | Kim, So-Yeon | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.contributor.author | Sung, Myung-Whun | - |
dc.contributor.author | Hah, J. Hun | - |
dc.date.accessioned | 2012-07-04T06:58:16Z | - |
dc.date.available | 2012-07-04T06:58:16Z | - |
dc.date.issued | 2010-12 | - |
dc.identifier.citation | TUMOR BIOLOGY; Vol.31 6; 659-666 | ko_KR |
dc.identifier.issn | 1010-4283 | - |
dc.identifier.uri | https://hdl.handle.net/10371/78446 | - |
dc.description.abstract | Suberoylanilide hydroxamic acid (SAHA) is one of the most widely used histone deacetylase inhibitors. However, the potential advantage of SAHA has not been sufficiently validated as an adjunct to gene therapy of head and neck squamous cell carcinoma (HNSCC). SAHA has been shown to boost the efficiency of gene transfer by upregulating the expression of coxsackie adenoviral receptor on treated cells. The p53 family genes, p63 and p73, have been shown to have characteristics similar to p53, and although they are not confirmed as tumor suppressors, DNA-damaging signals induce their overexpression. We previously reported that the adenovirus-mediated transfer of p63 or p73 showed an effective cancer-killing effect similar to that of p53. In this study, we combined SAHA with adenoviral delivery of p63 or p73 to enhance the efficiency of gene therapy. This combination resulted in a significantly enhanced cancer-killing effect in HNSCC cell lines but had no effect on normal human fibroblasts. SAHA treatment added to ad-p63/p73 gene delivery caused an increase in p21 expression and cleaved poly-ADP ribose polymerase. Our results indicate that adjuvant SAHA treatment could be developed as a therapeutic strategy to enhance the efficiency of adenoviral gene transfer in the treatment of cancer. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | SPRINGER | ko_KR |
dc.subject | Combination gene therapy | ko_KR |
dc.subject | p73 | ko_KR |
dc.subject | SAHA | ko_KR |
dc.subject | HNSCC | ko_KR |
dc.subject | p63 | ko_KR |
dc.title | A combination treatment with SAHA and ad-p63/p73 shows an enhanced anticancer effect in HNSCC | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 심선휘 | - |
dc.contributor.AlternativeAuthor | 이춘택 | - |
dc.contributor.AlternativeAuthor | 이재정 | - |
dc.contributor.AlternativeAuthor | 김소연 | - |
dc.contributor.AlternativeAuthor | 허대석 | - |
dc.contributor.AlternativeAuthor | 성명훈 | - |
dc.identifier.doi | 10.1007/s13277-010-0083-z | - |
dc.citation.journaltitle | TUMOR BIOLOGY | - |
dc.description.citedreference | Blumenschein GR, 2008, INVEST NEW DRUG, V26, P81, DOI 10.1007/s10637-007-9075-2 | - |
dc.description.citedreference | DeYoung MP, 2007, ONCOGENE, V26, P5169, DOI 10.1038/sj.onc.1210337 | - |
dc.description.citedreference | Lee JJ, 2006, CANCER BIOL THER, V5, P1502 | - |
dc.description.citedreference | DeYoung MP, 2006, CANCER RES, V66, P9362, DOI 10.1158/0008-5472.CAN-06-1619 | - |
dc.description.citedreference | Sakuma T, 2006, INT J ONCOL, V29, P117 | - |
dc.description.citedreference | Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013 | - |
dc.description.citedreference | Dokmanovic M, 2005, J CELL BIOCHEM, V96, P293, DOI 10.1002/jcb.20532 | - |
dc.description.citedreference | Kelly WK, 2005, J CLIN ONCOL, V23, P3923, DOI 10.1200/JCO.2005.14.167 | - |
dc.description.citedreference | Bhalla KN, 2005, J CLIN ONCOL, V23, P3971, DOI 10.1200/JCO.2005.16.600 | - |
dc.description.citedreference | Flores ER, 2005, CANCER CELL, V7, P363 | - |
dc.description.citedreference | Sniezek JC, 2004, LARYNGOSCOPE, V114, P2063, DOI 10.1097/01.mlg.0000149437.35855.4b | - |
dc.description.citedreference | Pong RC, 2003, CANCER RES, V63, P8680 | - |
dc.description.citedreference | Massion PP, 2003, CANCER RES, V63, P7113 | - |
dc.description.citedreference | Hu H, 2002, INT J CANCER, V102, P580, DOI 10.1002/ijc.10739 | - |
dc.description.citedreference | Jee YS, 2002, ANTICANCER RES, V22, P2629 | - |
dc.description.citedreference | Weber A, 2002, INT J CANCER, V99, P22, DOI 10.1002/ijc.10296 | - |
dc.description.citedreference | Marks PA, 2001, NAT REV CANCER, V1, P194 | - |
dc.description.citedreference | Dohn M, 2001, ONCOGENE, V20, P3193 | - |
dc.description.citedreference | Wang TY, 2001, HUM PATHOL, V32, P479, DOI 10.1053/hupa.2001.24324 | - |
dc.description.citedreference | Gong JG, 1999, NATURE, V399, P806 | - |
dc.description.citedreference | Shimada A, 1999, CANCER RES, V59, P2781 | - |
dc.description.citedreference | Bergelson JM, 1997, SCIENCE, V275, P1320 | - |
dc.description.tc | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.